Benjamin L. Liechty

Benjamin L. Liechty

Auto-generated profile, based on publicly available information

Benjamin L. Liechty

Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, USA

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 February 2024 in Nature Reviews Electrical Engineering
Verified
Journal Article
Closed access
PDF file
CBCagla Deniz Bahadir
Cagla Deniz Bahadir
MOMohamed Omar
Mohamed Omar
JRJacob Rosenthal
Jacob Rosenthal
LMLuigi Marchionni
Luigi Marchionni
BLBenjamin Liechty
Benjamin Liechty
MSMert R. Sabuncu
Mert R. Sabuncu

3 June 2022 in Scientific Reports
Verified
Journal Article
Open access
PDF file
SKSean H. Kim
Sean H. Kim
MRMichelle Roytman
Michelle Roytman
GMGabriela Madera
Gabriela Madera
RMRajiv S. Magge
Rajiv S. Magge
BLBenjamin Liechty
Benjamin Liechty
JIJana Ivanidze
Jana Ivanidze
Multiple approaches with [68Ga]-DOTATATE, a somatostatin analog PET radiotracer, have demonstrated clinical utility in evaluation of meningioma but have not been compared directly. Our purpose was to compare diagnostic performance of different approaches to quantitative brain [68Ga]-DOTATATE PET/MRI analysis in patients with suspected meningioma recurrence and to establish the optimal diagnostic threshold for each method. Patients with suspected meningioma were imaged prospectively with [68Ga]-DOTATATE brain PET/MRI. Lesions were classified as meningiomas and post-treatment change (PTC), using follow-up pathology and MRI as reference standard. Lesions were reclassified using the following methods: absolute maximum SUV threshold (SUV), SUV ratio (SUVR) to superior sagittal sinus (SSS) (SUVRsss), SUVR to the pituitary gland (SUVRpit), and SUVR to the normal brain parenchyma (SUVRnorm). Diagnostic performance of the four methods was compared using contingency tables and McNemar’s test. Previously published pre-determined thresholds were assessed where applicable. The optimal thresholds for each method were identified using Youden’s J statistics. 166 meningiomas and 41 PTC lesions were identified across 62 patients. SUV, SUVRsss, SUVRpit, and SUVRnorm of meningioma were significantly higher than those of PTC (P < 0.0001). The optimal thresholds for SUV, SUVRsss, SUVRpit, and SUVRnorm were 4.7, 3.2, 0.3, and 62.6, respectively. At the optimal thresholds, SUV had the highest specificity (97.6%) and SUVRsss had the highest sensitivity (86.1%). An ROC analysis of SUV, SUVRsss, SUVRpit, and SUVRnorm revealed AUC of 0.932, 0.910, 0.915, and 0.800, respectively (P < 0.0001). Developing a diagnostic threshold is key to wider clinical translation of [68Ga]-DOTATATE PET/MRI in meningioma evaluation. We found that the SUVRsss method may have the most robust combination of sensitivity and specificity in the diagnosis of meningioma in the post-treatment setting, with the optimal threshold of 3.2. Future studies validating our findings in different patient populations are needed to continue optimizing the diagnostic performance of [68Ga]-DOTATATE PET/MRI in meningioma patients.Trial registration: ClinicalTrials.gov Identifier: NCT04081701. Registered 9 September 2019. https://clinicaltrials.gov/ct2/show/NCT04081701.

31 August 2023 in Cold Spring Harbor Molecular Case Studies
Verified
Journal Article
Open access
PDF file
MAMajd Al Assaad
Majd Al Assaad
GGGunes Gundem
Gunes Gundem
BLBenjamin Liechty
Benjamin Liechty
ASAndrea Sboner
Andrea Sboner
JMJuan Medina
Juan Medina
JMJuan Miguel Mosquera
Juan Miguel Mosquera
Pilocytic astrocytomas are the most common pediatric brain tumors, typically presenting as low-grade neoplasms. We report two cases of pilocytic astrocytoma with atypical tumor progression. Case 1 involves a 12-yr-old boy with an unresectable suprasellar tumor, negative forBRAFrearrangement but harboring aBRAFp.V600E mutation. He experienced tumor size reduction and stable disease following dabrafenib treatment. Case 2 describes a 6-yr-old boy with a thalamic tumor that underwent multiple resections, with no actionable driver detected using targeted next-generation sequencing. Whole-genome and RNA-seq analysis identified an internal tandem duplication inFGFR1and RAS pathway activation. Future management options include FGFR1 inhibitors. These cases demonstrate the importance of escalating molecular diagnostics for pediatric brain cancer, advocating for early reflexing to integrative whole-genome sequencing and transcriptomic profiling when targeted panels are uninformative. Identifying molecular drivers can significantly impact treatment decisions and improve patient outcomes.

23 October 2023 in Molecular Cancer Research
Verified
Journal Article
Closed access
PDF file
KGKristyn Galbraith
Kristyn Galbraith
JSJonathan Serrano
Jonathan Serrano
GSGuomiao Shen
Guomiao Shen
ITIvy Tran
Ivy Tran
CSCheyanne C. Slocum
Cheyanne C. Slocum
MSMatija Snuderl
Matija Snuderl
DNA methylation is an essential molecular assay for central nervous system (CNS) tumor diagnostics. While some fusions define specific brain tumors, others occur across many different diagnoses. We performed a retrospective analysis of 219 primary CNS tumors with whole genome DNA methylation and RNA next-generation sequencing. DNA methylation profiling results were compared with RNAseq detected gene fusions. We detected 105 rare fusions involving 31 driver genes, including 23 fusions previously not implicated in brain tumors. In addition, we identified 6 multi-fusion tumors. Rare fusions and multi-fusion events can impact the diagnostic accuracy of DNA methylation by decreasing confidence in the result, such as BRAF, RAF, or FGFR1 fusions, or result in a complete mismatch, such as NTRK, EWSR1, FGFR, and ALK fusions. Implications: DNA methylation signatures need to be interpreted in the context of pathology and discordant results warrant testing for novel and rare gene fusions.

27 February 2025 in The Journal of Molecular Diagnostics
Verified
Journal Article
Closed access
KGKristyn Galbraith
Kristyn Galbraith
JWJamin Wu
Jamin Wu
KSKristin Sikkink
Kristin Sikkink
HMHussein Mohamed
Hussein Mohamed
DRDerek Reid
Derek Reid
MSMatija Snuderl
Matija Snuderl

1 January 2024 in Annals of Internal Medicine: Clinical Cases
Verified
Journal Article
Closed access
SBSamuel S. Bruce
Samuel S. Bruce
SMSantosh B. Murthy
Santosh B. Murthy
NPNeal S. Parikh
Neal S. Parikh
ASAndrew D. Schweitzer
Andrew D. Schweitzer
MRMichelle Roytman
Michelle Roytman
BNBabak B. Navi
Babak B. Navi